GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents
Business Wire India Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to – or even…
